{"protocolSection": {"identificationModule": {"nctId": "NCT01256086", "orgStudyIdInfo": {"id": "D-64428-3278"}, "secondaryIdInfos": [{"id": "IND #101,246", "type": "REGISTRY", "domain": "IND #101,246"}], "organization": {"fullName": "Viatris Inc.", "class": "INDUSTRY"}, "briefTitle": "Relative Potency of Formoterol Novolizer\u00ae 12 \u00b5g Compared to Formoterol Aerolizer\u00ae 12 \u00b5g", "officialTitle": "Relative Potency of Formoterol Novolizer\u00ae 12 \u00b5g Compared to Formoterol Aerolizer\u00ae 12 \u00b5g in Patients With Stable Asthma Using Bronchoprovocation With Methacholine as a Bioassay Randomized, Double-blind, Four-period, Four-sequence Cross-over Trial"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-12"}, "primaryCompletionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-07", "studyFirstSubmitQcDate": "2010-12-07", "studyFirstPostDateStruct": {"date": "2010-12-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-07-26", "resultsFirstSubmitQcDate": "2012-08-13", "resultsFirstPostDateStruct": {"date": "2012-09-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-02-04", "lastUpdatePostDateStruct": {"date": "2022-02-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "MEDA Pharma GmbH & Co. KG", "class": "INDUSTRY"}, "collaborators": [{"name": "ClinResearch, GmbH", "class": "OTHER"}, {"name": "Trio Clinical Research, LLC, Raleigh, USA", "class": "UNKNOWN"}, {"name": "NuCara Pharmacy, Waterloo, USA", "class": "UNKNOWN"}, {"name": "Prof. Hochhaus, Gainesville, USA", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to estimate the relative potency for bronchoprotective effect of formoterol Novolizer 12 \u00b5g (test) compared to formoterol Aerolizer 12 \u00b5g (reference)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 44, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "24 \u00b5g Formoterol Novolizer", "type": "EXPERIMENTAL", "description": "12\u00b5g Formoterol Novolizer#1 + 12\u00b5g Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2", "interventionNames": ["Drug: Formatris 24\u00b5g"]}, {"label": "12\u00b5g Formoterol Novolizer", "type": "EXPERIMENTAL", "description": "12\u00b5g Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2", "interventionNames": ["Drug: Formatris 12\u00b5g"]}, {"label": "24 \u00b5g Formoterol Aerolizer", "type": "ACTIVE_COMPARATOR", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + 12\u00b5g Formoterol Aerolizer #2", "interventionNames": ["Drug: Foradil P 24\u00b5g"]}, {"label": "12\u00b5g Formoterol Aerolizer", "type": "ACTIVE_COMPARATOR", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + Placebo Aerolizer #2", "interventionNames": ["Drug: Foradil P 12\u00b5g"]}], "interventions": [{"type": "DRUG", "name": "Formatris 24\u00b5g", "description": "12\u00b5g Formoterol Novolizer#1 + 12\u00b5g Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2", "armGroupLabels": ["24 \u00b5g Formoterol Novolizer"]}, {"type": "DRUG", "name": "Formatris 12\u00b5g", "description": "12\u00b5g Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2", "armGroupLabels": ["12\u00b5g Formoterol Novolizer"]}, {"type": "DRUG", "name": "Foradil P 24\u00b5g", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + 12\u00b5g Formoterol Aerolizer #2", "armGroupLabels": ["24 \u00b5g Formoterol Aerolizer"]}, {"type": "DRUG", "name": "Foradil P 12\u00b5g", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + Placebo Aerolizer #2", "armGroupLabels": ["12\u00b5g Formoterol Aerolizer"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "PC20 = Provocation Concentration of Methacholine That Cause a 20% Decrease in Forced Expiratory Volume in the First Second (FEV1)", "description": "The primary variable is the methacholine PC20 after inhalation of study medication; the PC20 is the concentration of methacholine that - despite protection by study medication - causes a 20% fall in FEV1 compared to the pre-methacholine (post-saline) level of the given study day.", "timeFrame": "60 min after application of study medication"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female patients aged from 18 to 60 years (inclusive).\n2. Patients with asthma indicated by\n\n   * history of asthma symptoms and\n   * airway hyperresponsiveness to methacholine with a provocation concentration of methacholine that cause a 20% decrease in FEV1 (PC20) \u22648 mg/ml at Visit 1.\n3. Patients with stable asthma condition with baseline forced expiratory volume in the first second (FEV1) \u226570% predicted at first visit.\n4. The PC20 methacholine should increase at least 4-fold after inhaling 24 \u03bcg of formoterol Aerolizer (2 applications of 12 \u03bcg) at Visit 2.\n5. Able to be taught correct inhalation technique for both devices at screening.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to formoterol, lactose, or methacholine.\n2. History of life-threatening asthma in the last three years.\n3. Major malignancies including pheochromocytoma within the last 5 years. Exception will be considered where malignancies have been resolved as judged by investigator.\n4. Pregnancy, breast-feeding, planned pregnancy during the study, or women of child-bearing potential not using adequate contraception. These methods include total abstinence (no sexual intercourse), oral contraceptives, an intrauterine device (IUD), an etonogestrel implant (Implanon), or medroxyprogesterone acetate injections (Depo-Provera shots). If one of these cannot be used, using contraceptive foam and a condom are recommended.\n\n   Lack of suitability for the study:\n5. Screening visit 2 has to be postponed repeatedly.\n6. Evidence of respiratory tract infection within 4 weeks before the study (screening visit 1).\n7. Seasonal or episodic exposure to an allergen or occupational chemical sensitizer which are likely to vary in symptom presentation and severity during the course of the study (e.g. ragweed sensitive patients in Iowa during Aug-Oct). This does not apply to patients who can be well controlled on therapy.\n8. History of non-reversible pulmonary disease; chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, or pulmonary fibrosis.\n9. History of severe cardiovascular, renal, neurologic, liver or endocrine dysfunction (patients with well-controlled hypertension, hypercholesterolemia, thyroid disease or diabetes may be included if medication for these diseases does not affect methacholine challenge or formoterol metabolism).\n10. History of hemophilia or coagulation disease.\n11. Electrocardiogram (ECG) abnormalities of clinical relevance, in particular abnormal prolongation of QT-interval (QTc according to Bazett in women \u2265450 msec, in men \u2265430 msec).\n12. Potassium level below lower limit of laboratory normal range plus 0.3 mmol/l as safety margin.\n13. Exacerbation of bronchial asthma requiring emergency department visit or hospitalization during the last 3 months prior to this study.\n14. Prior or concomitant treatment with systemic glucocorticosteroids during the last 3 months (a short course of oral corticosteroids for asthma is permissible if for \\<10 days and at least 30 days have passed).\n15. Use of long-acting \u00df2-agonists in last 3 weeks before the first methacholine challenge or during the study\n16. Change in dosage of other controller therapy (inhaled glucocorticosteroids, leukotriene modifier, slow-release theophylline) during the last 3 weeks before the first methacholine challenge or during the study.\n17. Use of short-acting \u00df2-agonists more than thrice a week in the previous month.\n18. Inability to temporary withhold the following medications/substances before lung function test:\n\n    * short-acting \u00df2-agonists and short-acting anticholinergics at least 6 hours,\n    * regular long-acting \u00df2-agonists at least 3 weeks,\n    * long-acting anticholinergics at least 36 hours,\n    * inhaled glucocorticosteroids at least 2 hours\n    * Disodium cromoglycate (DSCG) at least 24 hours,\n    * slow release theophylline at least 48 hours,\n    * rapid release theophylline at least 24 hours,\n    * caffeine at least 4 hours\n19. Patients with aspirin induced bronchospasm.\n20. Any treatment with \u00df2-antagonists (including eye drops).\n21. Non-cooperative patients, inability to perform outcome measurement correctly.\n22. Inability to measure PC20 methacholine after 24 \u03bcg of formoterol Aerolizer (PC20 \\>128 mg/ml).\n23. Current smokers or regular smokers during last 12 months or more than 10 pack-year history.\n24. Drug or alcohol abuse which would interfere with the patient's proper completion of the protocol assignment.\n\n    Administrative reasons:\n25. Participation in another clinical study within 1 month prior to or during this study\n26. Lack of ability or willingness to give informed consent.\n27. Lack of willingness to have personal study related data collected, archived or transmitted according to protocol.\n28. Personnel involved in the planning or conduct of the study.\n29. Anticipated non-availability for study visits/procedures.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Leslie Hendeles, Professor", "affiliation": "University of Florida, Gainesville, USA", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32160-0486", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "University of Iowa", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53705", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "During screening phase (within 14 days before but at latest 2 days before randomisation), 2 methacholine tests on separate days (with and without pre-medication) were performed to check the suitability of the patients.", "recruitmentDetails": "First patient was enrolled in December 2010, last patient completed in July 2011", "groups": [{"id": "FG000", "title": "N1A2A1N2", "description": "Treatment sequence 12 \u00b5g Novolizer - 24 \u00b5g Aerolizer - 12 \u00b5g Aerolizer - 24 \u00b5g Novolizer"}, {"id": "FG001", "title": "A1N1N2A2", "description": "Treatment sequence 12 \u00b5g Aerolizer - 12 \u00b5g Novolizer - 24 \u00b5g Novolizer - 24 \u00b5g Aerolizer"}, {"id": "FG002", "title": "N2A1A2N1", "description": "Treatment sequence 24 \u00b5g Novolizer - 12 \u00b5g Aerolizer - 24 \u00b5g Aerolizer - 12 \u00b5g Novolizer"}, {"id": "FG003", "title": "A2N2N1A1", "description": "Treatment sequence 24 \u00b5g Aerolizer - 24 \u00b5g Novolizer - 12 \u00b5g Novolizer - 12 \u00b5g Aerolizer"}], "periods": [{"title": "Treatment Day 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Day 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Day 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Day 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "N1A2A1N2", "description": "Sequence 1: N1A2A1N2 (Treatment day 1 to treatment day 4) N1 = 12\u00b5g Novolizer N2 = 24\u00b5g Novolizer A1 = 12\u00b5g Aerolizer A2 = 24\u00b5g Aerolizer"}, {"id": "BG001", "title": "A1N1N2A2", "description": "Sequence 2: A1N1N2A2 (Treatment day 1 to treatment day 4) N1 = 12\u00b5g Novolizer N2 = 24\u00b5g Novolizer A1 = 12\u00b5g Aerolizer A2 = 24\u00b5g Aerolizer"}, {"id": "BG002", "title": "N2A1A2N1", "description": "Sequence 3: N2A1A2N1 (Treatment day 1 to treatment day 4) N1 = 12\u00b5g Novolizer N2 = 24\u00b5g Novolizer A1 = 12\u00b5g Aerolizer A2 = 24\u00b5g Aerolizer"}, {"id": "BG003", "title": "A2N2N1A1", "description": "Sequence 4: A2N2N1A1 (Treatment day 1 to treatment day 4) N1 = 12\u00b5g Novolizer N2 = 24\u00b5g Novolizer A1 = 12\u00b5g Aerolizer A2 = 24\u00b5g Aerolizer"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "44"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "44"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31", "spread": "12"}, {"groupId": "BG001", "value": "35", "spread": "13"}, {"groupId": "BG002", "value": "26", "spread": "10"}, {"groupId": "BG003", "value": "28", "spread": "11"}, {"groupId": "BG004", "value": "30", "spread": "12"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "31"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "13"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "44"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "PC20 = Provocation Concentration of Methacholine That Cause a 20% Decrease in Forced Expiratory Volume in the First Second (FEV1)", "description": "The primary variable is the methacholine PC20 after inhalation of study medication; the PC20 is the concentration of methacholine that - despite protection by study medication - causes a 20% fall in FEV1 compared to the pre-methacholine (post-saline) level of the given study day.", "populationDescription": "Per Protocol Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "mg/ml", "timeFrame": "60 min after application of study medication", "groups": [{"id": "OG000", "title": "24 \u00b5g Formoterol Novolizer", "description": "12\u00b5g Formoterol Novolizer#1 + 12\u00b5g Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2"}, {"id": "OG001", "title": "12\u00b5g Formoterol Novolizer", "description": "12\u00b5g Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2"}, {"id": "OG002", "title": "24 \u00b5g Formoterol Aerolizer", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + 12\u00b5g Formoterol Aerolizer #2"}, {"id": "OG003", "title": "12\u00b5g Formoterol Aerolizer", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + Placebo Aerolizer #2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "38"}, {"groupId": "OG003", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.0", "spread": "138.8"}, {"groupId": "OG001", "value": "20.9", "spread": "130.1"}, {"groupId": "OG002", "value": "33.2", "spread": "96.4"}, {"groupId": "OG003", "value": "17.8", "spread": "172.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE_LEGACY", "nonInferiorityComment": "Relative potency of Novolizer compared to Aerolizer. Equivalence was to be concluded if the CI for the relative potency was completely covered by the interval (0.67, 1.50) according to OIP Guideline.", "paramType": "Relative potency", "paramValue": "1.13", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.94", "ciUpperLimit": "1.38", "estimateComment": "Fieller confidence interval for logarithm of relative potency"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "24 \u00b5g Formoterol Novolizer", "description": "12\u00b5g Formoterol Novolizer#1 + 12\u00b5g Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2", "seriousNumAffected": 0, "seriousNumAtRisk": 43, "otherNumAffected": 0, "otherNumAtRisk": 43}, {"id": "EG001", "title": "12\u00b5g Formoterol Novolizer", "description": "12\u00b5g Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2", "seriousNumAffected": 0, "seriousNumAtRisk": 41, "otherNumAffected": 0, "otherNumAtRisk": 41}, {"id": "EG002", "title": "24 \u00b5g Formoterol Aerolizer", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + 12\u00b5g Formoterol Aerolizer #2", "seriousNumAffected": 0, "seriousNumAtRisk": 41, "otherNumAffected": 0, "otherNumAtRisk": 41}, {"id": "EG003", "title": "12\u00b5g Formoterol Aerolizer", "description": "Placebo Novolizer#1 + Placebo Novolizer#2 + 12\u00b5g Formoterol Aerolizer#1 + Placebo Aerolizer #2", "seriousNumAffected": 1, "seriousNumAtRisk": 42, "otherNumAffected": 2, "otherNumAtRisk": 42}], "seriousEvents": [{"term": "laryngeal cancer stage 0", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Squamous cell carcinoma in situ of the left vocal cord was reported in a female patient with an ongoing history of worsening of vocal hoarseness since 2008. This event was assessed as unlikely related to the use of study drug (Aerolizer 12 \u00b5g)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}], "otherEvents": [{"term": "upper respiratory infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.1", "notes": "allergic reaction to a cat", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "INSTITUTION shall have the right to publish the results of its part of the study either independently or in collaboration with SPONSOR.In either case, INSTITUTION agrees to submit a copy of any manuscript and/or abstract to SPONSOR for review and comment sixty (60) days prior to its submission for publication. SPONSOR shall have said sixty (60) day period to respond to INSTITUTION with any requested revisions. INSTITUTION agrees to delete information identified by SPONSOR as confidential."}, "pointOfContact": {"title": "Prof. Dr. Leslie Hendeles", "organization": "University of Florida, Department of Pharmacotherapy and Tanslational Research, 100486 Gainesville, FL 32610", "email": "hendeles@cop.ufl.edu", "phone": "+1 352 279", "phoneExt": "6027"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Cerebral Blood Flow", "relevance": "HIGH"}, {"id": "M18666", "name": "Methacholine Chloride", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}